{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77","upperLimit":"97","value":"87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"The overall survival time is defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier. The overall survival rate at 6 months is defined as the percentage of participants who are alive at 6 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine 75 mg/m\\^2 IV day 1 and 2 Lenalidomide 25 mg PO days 1-21 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Maximum Tolerated Dose, Dose Level 4"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at 6 months","title":"Overall Survival (Phase II)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}